Abstract: System and method for detecting cognitive decline in a subject using a classification system for detecting cognitive decline in the subject based on a speech sample. The classification system is trained using speech data corresponding to audio recordings of speech from normal and cognitive decline patients to generate an ensemble classifier comprising a plurality of component classifiers and an ensemble module. Each of the plurality of component classifiers is a machine-learning classifier configured to generate a component output identifying a sample data as corresponding to a normal patient or a cognitive patient. The machine-learning classifier is generated based on a subset of available features. The ensemble module receives component outputs from all of the component classifiers and generates an ensemble output identifying the sample data as corresponding to a normal or cognitive decline patient based on the component outputs.

Abstract: System and method for detecting cognitive decline in a subject using a classification system for detecting cognitive decline in the subject based on a speech sample. The classification system is trained using speech data corresponding to audio recordings of speech from normal and cognitive decline patients to generate an ensemble classifier comprising a plurality of component classifiers and an ensemble module. Each of the plurality of component classifiers is a machine-learning classifier configured to generate a component output identifying a sample data as corresponding to a normal patient or a cognitive patient. The machine-learning classifier is generated based on a subset of available features. The ensemble module receives component outputs from all of the component classifiers and generates an ensemble output identifying the sample data as corresponding to a normal or cognitive decline patient based on the component outputs.

Abstract: The invention provides methods of identifying schizophrenia patients at risk for relapse. The invention also provides methods of early detection of schizophrenic relapse. The disclosed methods use monitoring of a subset of symptoms and/or one or more biomarkers. The symptom severity can be assessed using the Positive and Negative Syndrome Scale (PANSS) parameters. The methods of the invention can be used to provide early intervention to decrease or prevent relapse in schizophrenia patients.

Abstract: The invention provides methods of identifying schizophrenia patients at risk for relapse. The invention also provides methods of early detection of schizophrenic relapse. The disclosed methods use monitoring of a subset of symptoms and/or one or more biomarkers. The symptom severity can be assessed using the Positive and Negative Syndrome Scale (PANSS) parameters. The methods of the invention can be used to provide early intervention to decrease or prevent relapse in schizophrenia patients.

Abstract: A system and computer-implemented method for detecting return of depression of a patient is provided. The system comprises a wearable device configured to detect movement of the patient and configured to generate actigraphy data corresponding to the movement of the patient and a computing device for retrieving actigraphy data from the device. The system and method obtain training data, including training actigraphy data, over a training period and train an anomaly detector using the training data. The system and method subsequently obtain test data from the patient, extract a plurality of features from the test data, and analyze the extracted data using the trained anomaly detector. A self-report test is used to determine whether an anomaly identified by the anomaly detector indicates that the patient is likely to experience return of depression.

Abstract: System and method for detecting cognitive decline in a subject using a classification system for detecting cognitive decline in the subject based on a speech sample. The classification system is trained using speech data corresponding to audio recordings of speech from normal and cognitive decline patients to generate an ensemble classifier comprising a plurality of component classifiers and an ensemble module. Each of the plurality of component classifiers is a machine-learning classifier configured to generate a component output identifying a sample data as corresponding to a normal patient or a cognitive patient. The machine-learning classifier is generated based on a subset of available features. The ensemble module receives component outputs from all of the component classifiers and generates an ensemble output identifying the sample data as corresponding to a normal or cognitive decline patient based on the component outputs.

Abstract: System and method for detecting cognitive decline in a subject using a classification system for detecting cognitive decline in the subject based on a speech sample. The classification system is trained using speech data corresponding to audio recordings of speech from normal and cognitive decline patients to generate an ensemble classifier comprising a plurality of component classifiers and an ensemble module. Each of the plurality of component classifiers is a machine-learning classifier configured to generate a component output identifying a sample data as corresponding to a normal patient or a cognitive patient. The machine-learning classifier is generated based on a subset of available features. The ensemble module receives component outputs from all of the component classifiers and generates an ensemble output identifying the sample data as corresponding to a normal or cognitive decline patient based on the component outputs.

Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

Abstract: The invention provides methods of identifying schizophrenia patients at risk for relapse. The invention also provides methods of early detection of schizophrenic relapse. The disclosed methods use monitoring of a subset of symptoms and/or one or more biomarkers. The symptom severity can be assessed using the Positive and Negative Syndrome Scale (PANSS) parameters. The methods of the invention can be used to provide early intervention to decrease or prevent relapse in schizophrenia patients.

Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

Abstract: The present invention provides a method for diagnosing and detecting cancer. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in cancer (podocalyxin) and antibodies that bind podocalyxins. The present invention provides that podocalyxins are used as targets for screening agents that modulate podocalyxin activities. Further the present invention provides methods for treating diseases associated with podocalyxin expression.

Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

Abstract: Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of E-cadherin in comparison to healthy cells. Also provided are antagonists or agonists of E-cadherin, and methods for screening agents that modulate the E-cadherin level or activity in vivo or in vitro.

Abstract: The present invention provides a method for diagnosing and detecting cancer. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in cancer (podocalyxin) and antibodies that bind podocalyxins. The present invention provides that podocalyxins are used as targets for screening agents that modulate podocalyxin activities. Further the present invention provides methods for treating diseases associated with podocalyxin expression.

Abstract: Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of CD71 in comparison to healthy cells. Also provided are antagonists or agonists of CD71, and methods for screening agents that modulate the CD71 level or activity in vivo or in vitro.

Abstract: Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of CD51 in comparison to healthy cells. Also provided are antagonists or agonists of CD51, and methods for screening agents that modulate the CD51 level or activity in vivo or in vitro.